Targeting the translation machinery in cancer

[1]  F. Q. Ribeiro.  The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[2]  N. Sonenberg,et al.  Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3 , 2014, Oncogene.

[3]  J. Dufour,et al.  Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[4]  L. Platanias,et al.  Mnk kinases in cytokine signaling and regulation of cytokine responses , 2015, Biomolecular concepts.

[5]  J. Derisi,et al.  Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation , 2014, Genome Biology.

[6]  M. Piccart,et al.  Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis , 2014, Advances in Therapy.

[7]  A. Eggermont,et al.  eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies , 2014, Nature.

[8]  S. Cook,et al.  Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer. , 2014, Biochemical Society transactions.

[9]  Konstantinos J. Mavrakis,et al.  RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer , 2014, Nature.

[10]  S. Y. Cajal,et al.  The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets , 2014, Clinical and Translational Oncology.

[11]  R. E. Luna,et al.  Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G , 2014, Proceedings of the National Academy of Sciences.

[12]  David C. S. Huang,et al.  Simplified Silvestrol Analogues with Potent Cytotoxic Activity , 2014, ChemMedChem.

[13]  S. Suissa,et al.  Metformin and Cancer: Mounting Evidence Against an Association , 2014, Diabetes Care.

[14]  Alan G Hinnebusch,et al.  The scanning mechanism of eukaryotic translation initiation. , 2014, Annual review of biochemistry.

[15]  G. Ke,et al.  Decreased Expression of EIF4A1 After Preoperative Brachytherapy Predicts Better Tumor-Specific Survival in Cervical Cancer , 2014, International Journal of Gynecologic Cancer.

[16]  M. Koizumi,et al.  Attenuation of malignant phenotypes of breast cancer cells through eIF2α-mediated downregulation of Rac1 signaling. , 2014, International journal of oncology.

[17]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[18]  Stephen N. Jones,et al.  Oxygen sufficiency controls TOP mRNA translation via the TSC-Rheb-mTOR pathway in a 4E-BP-independent manner. , 2014, Journal of molecular cell biology.

[19]  D. Ruggero,et al.  Protein and Nucleotide Biosynthesis Are Coupled by a Single Rate-Limiting Enzyme, PRPS2, to Drive Cancer , 2014, Cell.

[20]  Sunita K. C. Basnet,et al.  Discovery of 5‐(2‐(Phenylamino)pyrimidin‐4‐yl)thiazol‐2(3H)‐one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation , 2014, ChemMedChem.

[21]  C. Proud,et al.  MAP kinase-interacting kinases--emerging targets against cancer. , 2014, Chemistry & biology.

[22]  S. Biffo,et al.  Translation factors and ribosomal proteins control tumor onset and progression: how? , 2014, Oncogene.

[23]  D. Walsh,et al.  Coupling 40S ribosome recruitment to modification of a cap-binding initiation factor by eIF3 subunit e , 2014, Genes & development.

[24]  J. Pelletier,et al.  Pancreatic tumours escape from translational control through 4E-BP1 loss , 2014, Oncogene.

[25]  D. Fruman,et al.  Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1 , 2014, PloS one.

[26]  Edward L Huttlin,et al.  Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5′TOP mRNA translation , 2014, Genes & development.

[27]  S. Cook,et al.  Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation , 2014, Journal of Cell Science.

[28]  S. Fan,et al.  Phosphorylated Mnk1 and eIF4E Are Associated with Lymph Node Metastasis and Poor Prognosis of Nasopharyngeal Carcinoma , 2014, PloS one.

[29]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[30]  P. Purushottamachar,et al.  First Mnks degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines , 2014, Oncotarget.

[31]  Jun O. Liu,et al.  Second-generation derivatives of the eukaryotic translation initiation inhibitor pateamine A targeting eIF4A as potential anticancer agents. , 2014, Bioorganic & medicinal chemistry.

[32]  D. Walsh,et al.  Coupling 40 S ribosome recruitment to modification of a cap-binding initiation factor by eIF 3 subunit e , 2014 .

[33]  J. Puglisi,et al.  Dynamic recognition of the mRNA cap by Saccharomyces cerevisiae eIF4E. , 2013, Structure.

[34]  N. Sonenberg,et al.  mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. , 2013, Cell metabolism.

[35]  M. Piccart,et al.  Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis , 2013, Advances in Therapy.

[36]  Philippe P Roux,et al.  Rapamycin Resistance: mTORC1 Substrates Hold Some of the Answers , 2013, Current Biology.

[37]  L. Foster,et al.  Protein synthesis rate is the predominant regulator of protein expression during differentiation , 2013, Molecular systems biology.

[38]  M. Pollak.  Potential applications for biguanides in oncology. , 2013, The Journal of clinical investigation.

[39]  Jeffrey Hill,et al.  Rational Design of Resorcylic Acid Lactone Analogues as Covalent MNK1/2 Kinase Inhibitors by Tuning the Reactivity of an Enamide Michael Acceptor , 2013, ChemMedChem.

[40]  C. Hetz,et al.  Targeting the unfolded protein response in disease , 2013, Nature Reviews Drug Discovery.

[41]  M. Hall.  Talks about TORCs: recent advancesin target of rapamycin signalling. On mTOR nomenclature. , 2013, Biochemical Society transactions.

[42]  C. Fraser,et al.  Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity , 2013, Proceedings of the National Academy of Sciences.

[43]  Rodney Colina.  Translational control of innate immune response , 2013 .

[44]  Luis Carrasco,et al.  Translation of viral mRNAs that do not require eIF4E is blocked by the inhibitor 4EGI-1 , 2013, Virology.

[45]  Hideo Kusano,et al.  LARP1 specifically recognizes the 3′ terminus of poly(A) mRNA , 2013, FEBS letters.

[46]  A. Koromilas,et al.  Control of oncogenesis by eIF2α phosphorylation: implications in PTEN and PI3K-Akt signaling and tumor treatment. , 2013, Future oncology.

[47]  J. Blay,et al.  Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  C. Pui,et al.  Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia , 2013, Pediatric blood & cancer.

[49]  R. Cencic,et al.  Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A , 2013, Blood Cancer Journal.

[50]  D. Sabatini,et al.  mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin , 2013, Science.

[51]  E. Pilozzi,et al.  Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway , 2013, Oncogene.

[52]  E. Papadopoulos,et al.  Hypoxia-inducible Factor-1α (HIF-1α) Promotes Cap-dependent Translation of Selective mRNAs through Up-regulating Initiation Factor eIF4E1 in Breast Cancer Cells under Hypoxia Conditions* , 2013, The Journal of Biological Chemistry.

[53]  S. Schuierer,et al.  Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex. , 2013, ACS chemical biology.

[54]  P. Ivanov,et al.  Post‐transcriptional regulatory networks in immunity , 2013, Immunological reviews.

[55]  N. Pavletich,et al.  mTOR kinase structure, mechanism and regulation by the rapamycin-binding domain , 2013, Nature.

[56]  S. Willimott,et al.  Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia , 2013, Clinical Cancer Research.

[57]  K. Borden,et al.  The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia , 2013, Leukemia.

[58]  C. Rommel,et al.  Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia , 2013, Leukemia.

[59]  Y. Martineau,et al.  Anti-oncogenic potential of the eIF4E-binding proteins , 2013, Oncogene.

[60]  D. Krueger,et al.  Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma , 2013, Neurology.

[61]  R. Kratzke,et al.  Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation. , 2013, Molecular pharmaceutics.

[62]  G. Thomas,et al.  Growth control and ribosomopathies. , 2013, Current opinion in genetics & development.

[63]  D. Ruggero.  Translational control in cancer etiology. , 2012, Cold Spring Harbor perspectives in biology.

[64]  M. Hall.  Talks About TORCs: Recent Advances in Target of Rapamycin Signalling , 2013 .

[65]  N. Sonenberg,et al.  Toward a genome-wide landscape of translational control. , 2013, Cold Spring Harbor perspectives in biology.

[66]  D. Walsh,et al.  Tinkering with translation: protein synthesis in virus-infected cells. , 2013, Cold Spring Harbor perspectives in biology.

[67]  N. Sonenberg,et al.  eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. , 2012, Cancer research.

[68]  N. Sonenberg,et al.  mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio , 2012, Oncotarget.

[69]  Philippe P Roux,et al.  Regulation of mRNA translation by signaling pathways. , 2012, Cold Spring Harbor perspectives in biology.

[70]  G. Mills,et al.  Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer , 2012, Breast Cancer Research.

[71]  S. Peluso,et al.  Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors. , 2012, Journal of medicinal chemistry.

[72]  M. Krzywinski,et al.  MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition , 2012, Oncogene.

[73]  M. Pollak.  Investigating metformin for cancer prevention and treatment: the end of the beginning. , 2012, Cancer discovery.

[74]  G. Wagner,et al.  Tumor suppression by small molecule inhibitors of translation initiation , 2012, Oncotarget.

[75]  P. Pandolfi,et al.  Up-regulation of Translation Eukaryotic Initiation Factor 4E in Nucleophosmin 1 Haploinsufficient Cells Results in Changes in CCAAT Enhancer-binding Protein α Activity , 2012, The Journal of Biological Chemistry.

[76]  Carleen Cullinane,et al.  Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. , 2012, Cancer cell.

[77]  Masahiro Morita,et al.  Distinct perturbation of the translatome by the antidiabetic drug metformin , 2012, Proceedings of the National Academy of Sciences.

[78]  Nicholas T. Ingolia,et al.  The translational landscape of mTOR signalling steers cancer initiation and metastasis , 2012, Nature.

[79]  S. Lowe,et al.  Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. , 2012, Cell reports.

[80]  N. Walker,et al.  Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction. , 2012, Journal of medicinal chemistry.

[81]  C. Wagner,et al.  Cap‐Dependent Translation Initiation Factor eIF4E: An Emerging Anticancer Drug Target , 2012, Medicinal research reviews.

[82]  D. Sabatini,et al.  A unifying model for mTORC1-mediated regulation of mRNA translation , 2012, Nature.

[83]  J. Pelletier,et al.  Emerging therapeutics targeting mRNA translation. , 2012, Cold Spring Harbor perspectives in biology.

[84]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[85]  E. Marcotte,et al.  Insights into the regulation of protein abundance from proteomic and transcriptomic analyses , 2012, Nature Reviews Genetics.

[86]  Dudley Lamming,et al.  Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity , 2012, Science.

[87]  Gordon B Mills,et al.  Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. , 2012, Cancer cell.

[88]  J. Thigpen.  Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer , 2012 .

[89]  R. Arceci.  Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .

[90]  S. Denoyelle,et al.  In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents. , 2012, Bioorganic & medicinal chemistry letters.

[91]  N. Sonenberg,et al.  Protein Synthesis and Translational Control , 2012 .

[92]  Xiancheng Li,et al.  Down-regulation of PDCD4 expression is an independent predictor of poor prognosis in human renal cell carcinoma patients , 2012, Journal of Cancer Research and Clinical Oncology.

[93]  Johanna Schott,et al.  Protein synthesis and translational control: at eye level with the ribosome , 2011, EMBO reports.

[94]  M. Hall,et al.  Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.

[95]  N. Ilić,et al.  PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis , 2011, Proceedings of the National Academy of Sciences.

[96]  M. Fishman,et al.  A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[97]  J. Supko,et al.  Chemical Genetics Identify eIF2α Kinase Heme Regulated Inhibitor as Anti-Cancer Target , 2011, Nature chemical biology.

[98]  E. Jacinto,et al.  mTOR complex 2 signaling and functions , 2011, Cell cycle.

[99]  Florence Dalenc,et al.  Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. , 2011, Cancer research.

[100]  Brian J. Bennett,et al.  Comparative Analysis of Proteome and Transcriptome Variation in Mouse , 2011, PLoS genetics.

[101]  M. Grever,et al.  Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells , 2011, The AAPS Journal.

[102]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[103]  S. Vajda,et al.  Blocking eIF4E-eIF4G Interaction as a Strategy To Impair Coronavirus Replication , 2011, Journal of Virology.

[104]  D. Ron,et al.  Selective Inhibition of a Regulatory Subunit of Protein Phosphatase 1 Restores Proteostasis , 2011, Science.

[105]  D. Sabatini,et al.  The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling , 2011, Science.

[106]  Tomoyuki Tsumuraya,et al.  Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. , 2011, Biochemical pharmacology.

[107]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[108]  Philippe P Roux,et al.  Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases , 2011, Microbiology and Molecular Reviews.

[109]  N. Sonenberg,et al.  Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. , 2011, Cancer research.

[110]  R. Hannan,et al.  Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. , 2011, Cancer research.

[111]  R. Cencic,et al.  Targeting Translation Dependence in Cancer , 2011, Oncotarget.

[112]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[113]  N. Sonenberg,et al.  Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling , 2011 .

[114]  R. Pearson.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2011 .

[115]  N. Sonenberg,et al.  mRNA translation and energy metabolism in cancer: the role of the MAPK and mTORC1 pathways. , 2011, Cold Spring Harbor symposia on quantitative biology.

[116]  Andrew M Hanby,et al.  Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer , 2011, Molecular Cancer.

[117]  H. Kitano,et al.  A comprehensive map of the mTOR signaling network , 2010, Molecular systems biology.

[118]  R. Memmott,et al.  Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis , 2010, Cancer Prevention Research.

[119]  P. Pandolfi,et al.  eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression , 2010, Proceedings of the National Academy of Sciences.

[120]  N. Hernandez,et al.  mTORC1 Directly Phosphorylates and Regulates Human MAF1 , 2010, Molecular and Cellular Biology.

[121]  D. Sabatini,et al.  Structure of the human mTOR complex I and its implications for rapamycin inhibition. , 2010, Molecular cell.

[122]  N. Sonenberg,et al.  mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs , 2010, Science.

[123]  D. Fruman,et al.  Targeting TOR dependence in cancer , 2010, Oncotarget.

[124]  S. Formenti,et al.  Translational control in cancer , 2010, Nature Reviews Cancer.

[125]  D. Felsher,et al.  MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.

[126]  K. Shokat,et al.  Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. , 2010, Cancer cell.

[127]  Jing Chen,et al.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor , 2010, Nature Medicine.

[128]  Lisa L. Smith,et al.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. , 2010, Cancer research.

[129]  Huiling Yang,et al.  Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma , 2010, Molecular Cancer.

[130]  S. Valentini,et al.  Functional significance of eIF5A and its hypusine modification in eukaryotes , 2010, Amino Acids.

[131]  N. Sonenberg,et al.  p53-dependent translational control of senescence and transformation via 4E-BPs. , 2009, Cancer cell.

[132]  J. Pelletier,et al.  c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy. , 2009, Cancer research.

[133]  T. Anthony,et al.  GCN2 Protein Kinase Is Required to Activate Amino Acid Deprivation Responses in Mice Treated with the Anti-cancer Agent l-Asparaginase* , 2009, The Journal of Biological Chemistry.

[134]  B. Coiffier,et al.  Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  B. Leber,et al.  Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. , 2009, Blood.

[136]  S. Ko,et al.  Inhibition of Ovarian Cancer Growth by a Tumor-Targeting Peptide That Binds Eukaryotic Translation Initiation Factor 4E , 2009, Clinical Cancer Research.

[137]  P. Levine,et al.  Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer , 2009, Nature Cell Biology.

[138]  C. Wagner,et al.  Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. , 2009, ACS chemical biology.

[139]  J. Deddens,et al.  eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. , 2009, Cancer research.

[140]  Zhihong Chen,et al.  Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A , 2009, Molecular Cancer Therapeutics.

[141]  R. Cencic,et al.  Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol , 2009, PloS one.

[142]  C. Chresta,et al.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.

[143]  V. Speirs,et al.  Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity , 2009, British Journal of Cancer.

[144]  Nicholas T. Ingolia,et al.  Genome-Wide Analysis in Vivo of Translation with Nucleotide Resolution Using Ribosome Profiling , 2009, Science.

[145]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[146]  A. Hinnebusch,et al.  Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets , 2009, Cell.

[147]  J. Blenis,et al.  Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy , 2009, Cell cycle.

[148]  Robbie Loewith,et al.  Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.

[149]  Yun Zhang,et al.  PDCD4 gene silencing in gliomas is associated with 5′CpG island methylation and unfavourable prognosis , 2008, Journal of cellular and molecular medicine.

[150]  O. Meyuhas,et al.  Chapter 3 Ribosomal Protein S6 Kinase , 2009 .

[151]  O. Meyuhas,et al.  Ribosomal protein S6 kinase from TOP mRNAs to cell size. , 2009, Progress in molecular biology and translational science.

[152]  T. Hoang,et al.  Stability of Eukaryotic Translation Initiation Factor 4E mRNA Is Regulated by HuR, and This Activity Is Dysregulated in Cancer , 2008, Molecular and Cellular Biology.

[153]  N. Sonenberg,et al.  Requirement of RNA Binding of Mammalian Eukaryotic Translation Initiation Factor 4GI (eIF4GI) for Efficient Interaction of eIF4E with the mRNA Cap , 2008, Molecular and Cellular Biology.

[154]  Robert J White.  RNA polymerases I and III, non-coding RNAs and cancer. , 2008, Trends in genetics : TIG.

[155]  J. Aguirre-Ghiso,et al.  Inhibition of eIF2α Dephosphorylation Maximizes Bortezomib Efficiency and Eliminates Quiescent Multiple Myeloma Cells Surviving Therapy , 2008 .

[156]  Sang Gyun Kim,et al.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation , 2008, Proceedings of the National Academy of Sciences.

[157]  R. Figlin.  Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC , 2008, Nature Clinical Practice Oncology.

[158]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[159]  B. Kong,et al.  Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma. , 2008, Anticancer research.

[160]  M. Pollak,et al.  Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. , 2008, Endocrine-related cancer.

[161]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[162]  R. Cencic,et al.  c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. , 2008, Cancer research.

[163]  S. Lowe,et al.  Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. , 2008, The Journal of clinical investigation.

[164]  A. Shimamura,et al.  Ribosomal dysfunction and inherited marrow failure , 2008, British journal of haematology.

[165]  C. Proud,et al.  The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). , 2008, Frontiers in bioscience : a journal and virtual library.

[166]  J. Zavadil,et al.  eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy , 2008, The Journal of cell biology.

[167]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[168]  W. Wilson,et al.  Lessons , Challenges , and Opportunities Strategies for Promoting Gender Equity in Developing Countries , 2008 .

[169]  S. Lowe,et al.  Dissecting eIF4E action in tumorigenesis. , 2007, Genes & development.

[170]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[171]  E. Chevet,et al.  Integrated endoplasmic reticulum stress responses in cancer. , 2007, Cancer research.

[172]  N. Sonenberg,et al.  Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. , 2007, Cancer research.

[173]  H. Allgayer,et al.  Loss of programmed cell death 4 expression marks adenoma‐carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer , 2007, Cancer.

[174]  Tao Wang,et al.  Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. , 2007, The Journal of clinical investigation.

[175]  Alicja Wolk,et al.  Diabetes mellitus and risk of breast cancer: A meta‐analysis , 2007, International journal of cancer.

[176]  J. Baselga,et al.  4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. , 2007, Cancer research.

[177]  O. Larsson,et al.  Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. , 2007, Cancer research.

[178]  B. Viollet,et al.  Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. , 2007, Cancer research.

[179]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[180]  Hans-Peter Lenhof,et al.  Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26‐27 in squamous cell carcinoma of the lung , 2007, International journal of cancer.

[181]  M. Waterfield,et al.  Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. , 2007, Cancer research.

[182]  A. Degterev,et al.  Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G , 2007, Cell.

[183]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[184]  Michael B. Mathews,et al.  Translational control in biology and medicine , 2007 .

[185]  R. Curi,et al.  Inhibition of eukaryotic translation initiation factor 5A (eIF5A) hypusination impairs melanoma growth , 2007, Cell biochemistry and function.

[186]  J. Pelletier,et al.  Initiation of protein synthesis by hepatitis C virus is refractory to reduced eIF2.GTP.Met-tRNA(i)(Met) ternary complex availability. , 2006, Molecular biology of the cell.

[187]  N. Sonenberg,et al.  Cap-Dependent Translational Inhibition Establishes Two Opposing Morphogen Gradients in Drosophila Embryos , 2006, Current Biology.

[188]  Michele Pagano,et al.  S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth , 2006, Science.

[189]  Claes Wahlestedt,et al.  Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure , 2006, Nucleic acids research.

[190]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[191]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[192]  J. Pelletier,et al.  Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A , 2006, Nature chemical biology.

[193]  G. Collins.  The next generation. , 2006, Scientific American.

[194]  R. Hresko,et al.  mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes* , 2005, Journal of Biological Chemistry.

[195]  Jun O. Liu,et al.  Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. , 2005, Molecular cell.

[196]  S. Larsson,et al.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[197]  D. Scheuner,et al.  ER stress‐regulated translation increases tolerance to extreme hypoxia and promotes tumor growth , 2005, The EMBO journal.

[198]  L. Beeren,et al.  The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro. , 2005, RNA.

[199]  F. Khuri,et al.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.

[200]  J. Pelletier,et al.  Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. , 2005, RNA.

[201]  N. Sonenberg,et al.  Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[202]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[203]  Junying Yuan,et al.  A Selective Inhibitor of eIF2α Dephosphorylation Protects Cells from ER Stress , 2005, Science.

[204]  L. S. Harrington,et al.  Restraining PI3K: mTOR signalling goes back to the membrane. , 2005, Trends in biochemical sciences.

[205]  Robert J. White,et al.  RNA polymerases I and III, growth control and cancer , 2005, Nature Reviews Molecular Cell Biology.

[206]  N. Moussatché,et al.  Protein synthesis in vaccinia virus-infected cells , 2005, Archives of Virology.

[207]  A. Kentsis,et al.  Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[208]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[209]  K. Borden,et al.  Phosphorylation of the Eukaryotic Translation Initiation Factor eIF4E Contributes to Its Transformation and mRNA Transport Activities , 2004, Cancer Research.

[210]  P. Kirschner,et al.  A five-dimensional framework for authentic assessment , 2004 .

[211]  R. Wek,et al.  Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[212]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[213]  N. Sonenberg,et al.  Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. , 2004, Cancer cell.

[214]  P. Pandolfi,et al.  The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis , 2004, Nature Medicine.

[215]  A. Gingras,et al.  Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases , 2004, The EMBO journal.

[216]  N. Sonenberg,et al.  eIF4E – from translation to transformation , 2004, Oncogene.

[217]  J. Graff,et al.  eIF-4E expression and its role in malignancies and metastases , 2004, Oncogene.

[218]  J. Avruch,et al.  Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[219]  King-Jen Chang,et al.  Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome , 2004, Journal of surgical oncology.

[220]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[221]  I. Grummt,et al.  mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. , 2004, Genes & development.

[222]  N. Sonenberg,et al.  The protein kinase PKR: a molecular clock that sequentially activates survival and death programs , 2004, The EMBO journal.

[223]  E. Schmidt,et al.  Activated eIF4E-binding Protein Slows G1 Progression and Blocks Transformation by c-myc without Inhibiting Cell Growth* , 2004, Journal of Biological Chemistry.

[224]  Iver Petersen,et al.  Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis , 2003, The Journal of pathology.

[225]  N. Sonenberg,et al.  The Transformation Suppressor Pdcd4 Is a Novel Eukaryotic Translation Initiation Factor 4A Binding Protein That Inhibits Translation , 2003, Molecular and Cellular Biology.

[226]  B. Tursun,et al.  A novel two-step mechanism for removal of a mitochondrial signal sequence involves the mAAA complex and the putative rhomboid protease Pcp1. , 2002, Journal of molecular biology.

[227]  A. Ryazanov,et al.  Regulation of elongation factor-2 kinase by pH. , 2002, Biochemistry.

[228]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[229]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[230]  H. Gram,et al.  Negative Regulation of Protein Translation by Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 , 2001, Molecular and Cellular Biology.

[231]  A. Hinnebusch,et al.  Tight Binding of the Phosphorylated α Subunit of Initiation Factor 2 (eIF2α) to the Regulatory Subunits of Guanine Nucleotide Exchange Factor eIF2B Is Required for Inhibition of Translation Initiation , 2001, Molecular and Cellular Biology.

[232]  X. Ding,et al.  Prevention of pancreatic cancer induction in hamsters by metformin. , 2001, Gastroenterology.

[233]  N. Sonenberg,et al.  The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure. , 2001, RNA.

[234]  G. Scheper,et al.  The Mitogen-Activated Protein Kinase Signal-Integrating Kinase Mnk2 Is a Eukaryotic Initiation Factor 4E Kinase with High Levels of Basal Activity in Mammalian Cells , 2001, Molecular and Cellular Biology.

[235]  C. Wagner,et al.  Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides , 2000, Medicinal research reviews.

[236]  M. Schapira,et al.  Regulated translation initiation controls stress-induced gene expression in mammalian cells. , 2000, Molecular cell.

[237]  Benjamin D. L. Li,et al.  Progression of eIF4E gene amplification and overexpression in benign and malignant tumors of the head and neck , 2000, Cancer.

[238]  A. De Benedetti,et al.  Antisense RNA to eIF4E Suppresses Oncogenic Properties of a Head and Neck Squamous Cell Carcinoma Cell Line , 2000, The Laryngoscope.

[239]  L. New,et al.  Phosphorylation of eIF-4E on Ser 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies. , 2000, Molecular cell biology research communications : MCBRC.

[240]  S. Gygi,et al.  Serum‐stimulated, rapamycin‐sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI , 2000, The EMBO journal.

[241]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[242]  A. De Benedetti,et al.  Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[243]  A. Gingras,et al.  Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. , 1999, Molecular cell.

[244]  S. Gygi,et al.  Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. , 1999, Genes & development.

[245]  I. London,et al.  Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis , 1999, Oncogene.

[246]  Jonathan A. Cooper,et al.  Phosphorylation of the Cap-Binding Protein Eukaryotic Translation Initiation Factor 4E by Protein Kinase Mnk1 In Vivo , 1999, Molecular and Cellular Biology.

[247]  A. Gingras,et al.  Human eukaryotic translation initiation factor 4G (eIF4G) recruits Mnk1 to phosphorylate eIF4E , 1999, The EMBO journal.

[248]  A. Gingras,et al.  eIF4E activity is regulated at multiple levels. , 1999, The international journal of biochemistry & cell biology.

[249]  G. Wagner,et al.  The interaction of eIF4E with 4E‐BP1 is an induced fit to a completely disordered protein , 1998, Protein science : a publication of the Protein Society.

[250]  J. Avruch,et al.  Amino Acid Sufficiency and mTOR Regulate p70 S6 Kinase and eIF-4E BP1 through a Common Effector Mechanism* , 1998, The Journal of Biological Chemistry.

[251]  S. Snyder,et al.  RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[252]  A. Gingras,et al.  4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. , 1998, Genes & development.

[253]  M. Kasuga,et al.  Regulation of eIF-4E BP1 Phosphorylation by mTOR* , 1997, The Journal of Biological Chemistry.

[254]  A. Gingras,et al.  Structure of translation factor elF4E bound to m7GDP and interaction with 4E-binding protein , 1997, Nature Structural Biology.

[255]  Benjamin D. L. Li,et al.  Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas , 1997, Oncogene.

[256]  Christine C. Hudson,et al.  Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. , 1997, Science.

[257]  G. Brown,et al.  Cellular energy utilization and molecular origin of standard metabolic rate in mammals. , 1997, Physiological reviews.

[258]  Jonathan A. Cooper,et al.  Mitogen‐activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2 , 1997, The EMBO journal.

[259]  Tony Hunter,et al.  MNK1, a new MAP kinase‐activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates , 1997, The EMBO journal.

[260]  C. Berset,et al.  A novel inhibitor of cap‐dependent translation initiation in yeast: p20 competes with eIF4G for binding to eIF4E , 1997, The EMBO journal.

[261]  N. Sonenberg,et al.  Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc , 1996, Molecular and cellular biology.

[262]  E. Schuman,et al.  A Requirement for Local Protein Synthesis in Neurotrophin-Induced Hippocampal Synaptic Plasticity , 1996, Science.

[263]  An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. , 1996, Molecular and cellular biology.

[264]  A. Gingras,et al.  4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[265]  A. De Benedetti,et al.  Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: Implications for tumor angiogenesis , 1996, International journal of cancer.

[266]  A. Gingras,et al.  Rapamycin blocks the phosphorylation of 4E‐BP1 and inhibits cap‐dependent initiation of translation. , 1996, The EMBO journal.

[267]  F. Buttgereit,et al.  A hierarchy of ATP-consuming processes in mammalian cells. , 1995, The Biochemical journal.

[268]  M. Andreeff,et al.  Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. , 1995, Blood.

[269]  N. Sonenberg,et al.  Eukaryotic Translation Initiation Factor 4E Regulates Expression of Cyclin D1 at Transcriptional and Post-transcriptional Levels (*) , 1995, The Journal of Biological Chemistry.

[270]  The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins. , 1995, Molecular and cellular biology.

[271]  N. Sonenberg,et al.  Abrogation of translation initiation factor eIF‐2 phosphorylation causes malignant transformation of NIH 3T3 cells. , 1995, The EMBO journal.

[272]  S. Schreiber,et al.  Control of p70 S6 kinase by kinase activity of FRAP in vivo , 1995, Nature.

[273]  M. H. Park,et al.  Antiproliferative effects of inhibitors of deoxyhypusine synthase. Inhibition of growth of Chinese hamster ovary cells by guanyl diamines. , 1994, The Journal of biological chemistry.

[274]  A. Gingras,et al.  Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function , 1994, Nature.

[275]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[276]  N. Sonenberg,et al.  Dominant negative mutants of mammalian translation initiation factor eIF‐4A define a critical role for eIF‐4F in cap‐dependent and cap‐independent initiation of translation. , 1994, The EMBO journal.

[277]  A. De Benedetti,et al.  Decreasing the level of translation initiation factor 4E with antisense rna causes reversal of ras‐mediated transformation and tumorigenesis of cloned rat embryo fibroblasts , 1993, International journal of cancer.

[278]  A. Hinnebusch.  Gene‐specific translational control of the yeast GCN4 gene by phosphorylation of eukaryotic initiation factor 2 , 1993, Molecular microbiology.

[279]  K. Isselbacher,et al.  Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[280]  N. Sonenberg,et al.  mRNAs containing extensive secondary structure in their 5′ non‐coding region translate efficiently in cells overexpressing initiation factor eIF‐4E. , 1992, The EMBO journal.

[281]  A. Hinnebusch,et al.  Phosphorylation of initiation factor 2α by protein kinase GCN2 mediates gene-specific translational control of GCN4 in yeast , 1992, Cell.

[282]  A. De Benedetti,et al.  Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F , 1991, Molecular and cellular biology.

[283]  N. Sonenberg,et al.  Translational control of ornithine aminotransferase. Modulation by initiation factor eIF-4E. , 1991, The Journal of biological chemistry.

[284]  J. Heitman,et al.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast , 1991, Science.

[285]  J. Avruch,et al.  Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein kinase. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[286]  N. Sonenberg,et al.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap , 1990, Nature.

[287]  S. Segawa,et al.  End of the beginning , 1990, Nature.

[288]  E. Roth,et al.  Asparaginase‐induced derangements of glutamine metabolism: the pathogenetic basis for some drug‐related side‐effects , 1988, European journal of clinical investigation.

[289]  J. Hershey,et al.  Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. , 1987, The Journal of biological chemistry.

[290]  A. Hinnebusch,et al.  Multiple upstream AUG codons mediate translational control of GCN4 , 1986, Cell.

[291]  R. Rhoads,et al.  Immunological detection of the messenger RNA cap-binding protein. , 1985, The Journal of biological chemistry.

[292]  A. Konieczny,et al.  Purification of the eukaryotic initiation factor 2-eukaryotic initiation factor 2B complex and characterization of its guanine nucleotide exchange activity during protein synthesis initiation. , 1983, The Journal of biological chemistry.

[293]  M. Clemens,et al.  Phosphorylation inhibits guanine nucleotide exchange on eukaryotic initiation factor 2 , 1982, Nature.

[294]  H. Green,et al.  Changes in RNA in relation to growth of the fibroblast. IV. Alterations in theproduction and processing of mRNA and rRNA in resting and growing cells , 1976, The Journal of cell biology.

[295]  S. Pestka,et al.  Inhibition of Protein Synthesis in Intact HeLa Cells , 1975, Antimicrobial Agents and Chemotherapy.

[296]  M. Huang,et al.  Harringtonine, an inhibitor of initiation of protein biosynthesis. , 1975, Molecular pharmacology.

[297]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. , 1975, The Journal of antibiotics.

[298]  A. Khan,et al.  L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. , 1967, JAMA.